During the last three months, 5 analysts shared their evaluations of Repligen (NASDAQ:RGEN), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ratings, ...

If you are wondering whether Repligen at around US$119.99 is a bargain or still looks expensive, you are not alone. That is exactly what this article aims to unpack for you. Over the past week the ...

Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...

We recently published Top 10 Stock Recommendations You Can’t Miss Amid Growing AI Bubble Fears. Repligen Corporation (NASDAQ:RGEN) is one of the top recommended stocks. Dan Veru, Palisade Capital ...

Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble ...

In the latest quarter, 6 analysts provided ratings for Repligen (NASDAQ:RGEN), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the ...

What Happened? A number of stocks fell in the afternoon session after the February jobs report revealed an unexpected ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Repligen (NASDAQ:RGEN) in the last three months. The following table encapsulates their recent ...

We recently published a list of Top 10 Stocks to Buy According to 12 West Capital Management. In this article, we are going to take a look at where Repligen Corporation (NASDAQ:RGEN) stands against ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q4 CY2025 results exceeding the market’s revenue expectations, with sales up 18.1% year on year to $197.9 million. The ...